Merck (MRK) delivered earnings and revenue surprises of +17.45% and +4.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Norwegian Cruise Line (NCLH) delivered earnings and revenue surprises of +20.43% and +2.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) delivered earnings and revenue surprises of +38.10% and +1.42%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
RXO (RXO) delivered earnings and revenue surprises of +12.50% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
KBR (KBR) delivered earnings and revenue surprises of +10.89% and -1.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Cognizant (CTSH) delivered earnings and revenue surprises of +2.06% and +0.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Cisco has released patches to address a high-severity security flaw in Secure Firewall Adaptive Security Appliance (ASA) Software and Secure Firewall Threat Defense (FTD) Software that it said has been exploited in the wild.
The vulnerability, tracked as CVE-2026-76418, is rated 8.6 on the CVSS scoring system. Successful exploitation could allow an unauthenticated, remote attacker to cause the
In recent trading, shares of Bausch + Lomb Corporation (Symbol: BLCO) have crossed above the average analyst 12-month target price of $19.47, changing hands for $20.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra
In recent trading, shares of Bausch + Lomb Corporation (Symbol: BLCO) have crossed above the average analyst 12-month target price of $19.47, changing hands for $20.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra
KBR, Inc. reported its third quarter fiscal 2026 results, with revenues of $2.0 billion, up 5% compared to the third quarter fiscal 2025. Net income attributable to KBR was $133 million, up 16% from the prior-year period, while operating income was $186 million, down 3%. Diluted
On October 28, 2026, Dr. Reddy's Laboratories Limited announced that the United States Food & Drug Administration has classified the inspection outcome for its FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh, as Voluntary Action Indicated. The inspection, which was a Pre-
Pilgrim's Pride Corporation reported third quarter 2026 financial results, including net sales of $4.7 billion. The company reported GAAP net income of $116.3 million and GAAP EPS of $0.49, compared to U.S. GAAP EPS of $ 1.44 in the prior year period. Adjusted EBITDA was $316.3 m
In recent trading, shares of Fortive Corp (Symbol: FTV) have crossed above the average analyst 12-month target price of $62.40, changing hands for $64.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio
In recent trading, shares of Fortive Corp (Symbol: FTV) have crossed above the average analyst 12-month target price of $62.40, changing hands for $64.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio
In recent trading, shares of Stanley Black & Decker Inc (Symbol: SWK) have crossed above the average analyst 12-month target price of $99.82, changing hands for $100.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: do
In recent trading, shares of Stanley Black & Decker Inc (Symbol: SWK) have crossed above the average analyst 12-month target price of $99.82, changing hands for $100.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: do
In recent trading, shares of Viavi Solutions Inc (Symbol: VIA) have crossed above the average analyst 12-month target price of $36.30, changing hands for $36.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v